Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.

Non-ischemic cardiomyopathy

Recurrence of left ventricular dysfunction or heart failure at 6 months (any of the following events): Decrease in LVEF >10% and LVEF <50% or; decrease in LVEF >10% and an increase in the left ventricular end-systolic volume >15% or; onset of heart failure symptoms accompanied by an elevation in NT-proBNP requiring initiation of treatment with oral, subcutaneous, or intravenous loop diuretic therapy.

Emergency or day care hospital visits for heart failure at 6 and 12 months, Hospital admissions for heart failure at 6 and 12 months, Ventricular arrhythmias at 6 and 12 months, Supraventricular arrhythmias at 6 and 12 months, NT-proBNP levels at 6 and 12 months, NYHA class at 6 and 12 months, Quality of life at 6 and 12 months, Recurrence of left ventricular dysfunction or heart failure (as defined for the primary endpoint) at 12 months.

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Spain